FindTrial
Sign In

A Clinical trial to study the effect of antitubercular treatment for period of 6 months verses 9 months in female genital tuberculosis.

A Study on Treatment of Genital Tuberculosis : A Randomized Controlled Trial of Either Discontinuation at 6 Months or Continuation Till 9 Months After Initial Response to 6 Months RNTCP Category 1 Treatment.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/001088
Enrollment
175
Registered
2010-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Female Genital Tuberculosis

Interventions

Intervention1: Group I patients will be given standard antituberculous therapy ( ATT) under directly observed treatment shortcourse( DOTS) as rifampicin, isoniazid, pyrazinamide and ethambutol for 2 m

Sponsors

Central TB Division Ministry of Health and Family Welfare Govt of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)All women found to have genital tuberculosis on clinical examination or on laparoscopy/hysteroscopy and confirmed by AFB culture, smear or histopathology 2)Patient willing to participate in the study

Exclusion criteria

Exclusion criteria: 1. Any gynecological malignancy. 2. Co-morbid conditions like HIV positive women. 3. Retreatment cases

Design outcomes

Primary

MeasureTime frame
Cure from the disease.Timepoint: 6 months—

Secondary

MeasureTime frame
Difference in the stigmata of the disease in 6 month verses 9 monthsTimepoint: 6 month verses 9 months—

Countries

India

Contacts

Public ContactDr Jai Bhagwan Sharma

All India Institute of Medical Sciences

jbsharma2000@gmail.com011-26589665

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 13, 2026